Key Points - Kirby McInerney LLP reminds Capricor Therapeutics, Inc. investors of the September 28, 2026 deadline to seek the lead plaintiff role in a federal securities class action. - Pomerantz LLP announces a class action lawsuit has been filed against Capricor Therapeutics, Inc., advising affected investors to contact them. - Kaplan Fox & Kilsheimer...
Key Points - Dave & Buster's stock price dropped significantly after weaker-than-expected Q2 results - Shares...
Vaxart, Inc. (VXRT) is currently $0.4901 — here's the support-and-resistance map drawn from swing pivots, volume...
By KlickAnalytics Data InsightsSeptember 15, 2026 · 4:00 PM ETHeavy trading swept through NN, Inc. in...
Rather than pick a side, this is the evidence on each. Coda Octopus Group, Inc. (CODA)...
from Lake Street issued a price target of $44.00 for FTK on 2026-09-15 12:47:10.The adjusted price target was set to $44.00.At the time of the announcement, FTK was trading at...
from Lake Street issued a price target of $15.00 for PAYS on 2026-09-15 12:46:11.The adjusted price target was set to $15.00.At the time of the announcement, PAYS was trading at...
Sean Milligan from Needham issued a price target of $10.00 for EOSE on 2026-09-15 11:24:00.The adjusted price target was set to $10.00.At the time of the announcement, EOSE was trading...
Nick Abbott from Wells Fargo issued a price target of $3.00 for CLLS on 2026-09-15 10:22:07.The adjusted price target was set to $3.00.At the time of the announcement, CLLS was...
Andres Maldonado from H.C. Wainwright issued a price target of $18.00 for VSTM on 2026-09-14 11:35:00.The adjusted price target was set to $18.00.At the time of the announcement, VSTM was...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
